Literature DB >> 7750027

Ipriflavone improves bone density and biomechanical properties of adult male rat bones.

R Civitelli1, S H Abbasi-Jarhomi, L R Halstead, A Dimarogonas.   

Abstract

To assess the potential impact of ipriflavone on the biomechanical properties and mineral composition of bone, we administered two doses (200 or 400 mg/kg bw) of the drug orally to adult male rats for 1 month. Bone biomechanics were evaluated by vibration damping, an index of strain energy loss, and impact strength (the amount of energy required to fracture after a single impact). At the higher dose, ipriflavone significantly decreased vibration damping of rat femurs by 23.0 +/- 9.8% compared with control, vehicle-treated animals, suggesting a higher capacity to withstand dynamic stress. This result was confirmed by the impact strength studies showing that a higher energy (49.6 +/- 21.3% above control) was required to fracture femurs of rat treated with 400 mg/kg bw ipriflavone. The high dose of ipriflavone increased bone mineral density, assessed by both volume displacement and ash analysis (4.2% and 2.5% above controls, respectively). The relative content of calcium, phosphorus, and magnesium in the ashes was not different among the treated and untreated groups, indicating that no gross abnormalities in mineral composition of bone occurred after ipriflavone administration. Similarly, there were no differences in serum calcium and magnesium levels between treated and control animals at the end of the study, whereas lower circulating phosphorus levels were detected in the latter. Ipriflavone treatment was not associated with significant changes in serum alkaline phosphatase nor type I collagen telopeptide levels, two markers of bone turnover. In summary, 1-month treatment with ipriflavone increased bone density and improved the biomechanical properties of adult rat male bones without altering mineral composition.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7750027     DOI: 10.1007/BF00298613

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  22 in total

1.  Bone strength: the bottom line.

Authors:  T A Einhorn
Journal:  Calcif Tissue Int       Date:  1992-11       Impact factor: 4.333

2.  Material damping for monitoring of density and strength of bones.

Authors:  A D Dimarogonas; S H Abbasi-Jahromi; L V Avioli
Journal:  Calcif Tissue Int       Date:  1993-03       Impact factor: 4.333

3.  Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.

Authors:  M Gambacciani; A Spinetti; B Cappagli; F Taponeco; R Felipetto; D Parrini; N Cappelli; P Fioretti
Journal:  J Endocrinol Invest       Date:  1993-05       Impact factor: 4.256

4.  Monitoring of fracture healing by lateral and axial vibration analysis.

Authors:  G Nikiforidis; A Bezerianos; A Dimarogonas; C Sutherland
Journal:  J Biomech       Date:  1990       Impact factor: 2.712

5.  Effect of ipriflavone and estrogen on the differentiation and proliferation of osteogenic cells.

Authors:  Y Kakai; T Kawase; T Nakano; Y Mikuni-Takagaki; S Saito
Journal:  Calcif Tissue Int       Date:  1992       Impact factor: 4.333

6.  The effect of ipriflavone (TC-80) on bone resorption in tissue culture.

Authors:  M Tsuda; T Kitazaki; T Ito; T Fujita
Journal:  J Bone Miner Res       Date:  1986-04       Impact factor: 6.741

7.  The effect of ipriflavone treatment on osteoporosis induced by immobilization.

Authors:  I Földes; M Rapcsák; A Szöör; J Gyarmati; T Szilágyi
Journal:  Acta Morphol Hung       Date:  1988

8.  Effect of ipriflavone on glucocorticoid-induced osteoporosis in rats.

Authors:  I Yamazaki; A Shino; Y Shimizu; R Tsukuda; Y Shirakawa; M Kinoshita
Journal:  Life Sci       Date:  1986-03-10       Impact factor: 5.037

9.  Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass.

Authors:  M Valente; L Bufalino; G N Castiglione; R D'Angelo; A Mancuso; P Galoppi; L Zichella
Journal:  Calcif Tissue Int       Date:  1994-05       Impact factor: 4.333

10.  Stimulation of human osteoblast differentiation and function by ipriflavone and its metabolites.

Authors:  S L Cheng; S F Zhang; T L Nelson; P M Warlow; R Civitelli
Journal:  Calcif Tissue Int       Date:  1994-11       Impact factor: 4.333

View more
  4 in total

1.  Ipriflavone for the treatment of osteoporosis.

Authors:  Y K Choi; I K Han; H K Yoon
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

2.  Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.

Authors:  S Adami; L Bufalino; R Cervetti; C Di Marco; O Di Munno; L Fantasia; G C Isaia; U Serni; L Vecchiet; M Passeri
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

3.  Ipriflavone does not alter bone apatite crystal structure in adult male rats.

Authors:  C Ghezzo; R Civitelli; S Cadel; G Borelli; M Maiorino; L Bufalino; S Bongrani
Journal:  Calcif Tissue Int       Date:  1996-12       Impact factor: 4.333

Review 4.  Perspectives of pharmacological treatment in otosclerosis.

Authors:  Balázs Liktor; Zoltán Szekanecz; Tamás József Batta; István Sziklai; Tamás Karosi
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-07-29       Impact factor: 2.503

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.